Argus keeps a Buy rating and $420 price target on Vertex Pharmaceuticals while naming the stock as one of the firm’s 2024 Top Picks. The company has recently reported positive Phase 2 results for an investigative new drug that could serve as a non-opioid treatment option for acute pain, and presented positive results from its ongoing clinical trial of VX-880, an investigational stem cell-derived islet cell therapy for type 1 diabetes, and given the company’s continued pipeline progress and financial strength, the firm remains positive on the stock, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VRTX:
- The Smid-cap biotech stocks to own in 2024, according to Bernstein
- Vertex Pharmaceuticals named a ‘Catalyst Driven Idea’ at Morgan Stanley
- Charles River, Vertex reach important milestone in cell therapy collaboration
- Biotech Alert: Searches spiking for these stocks today
- Crispr Therapeutics positioned for European approval, says Piper Sandler